Arcus Biosciences, Inc. cash flow to debt ratio of -430.36% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Arcus Biosciences, Inc.'s free cash flow has decreased 175.00% from $-176.00M last year to $-484.00M, signaling decreasing performance

Arcus Biosciences, Inc.'s debt to equity ratio is 0.25, which means that the company's assets are healthy financed, signaling financial stability.

Arcus Biosciences, Inc.'s debt has increased relative to shareholder equity from 0.12 last year to 0.25 today, signaling weakened financials

Arcus Biosciences, Inc. has a net cash position, so leverage is healthy.

Arcus Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Arcus Biosciences, Inc.'s profit margin has decreased (252.20%) in the last year from -109.69% to -386.32%, signaling decreasing performance

Arcus Biosciences, Inc.'s short-term assets of $1.01B exceed its short-term liabilities of $231.00M

Arcus Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Arcus Biosciences, Inc.'s return on equity of -87.98%, is lower than 15.00%, indicating bad performance

Arcus Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Arcus Biosciences, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Arcus Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Arcus Biosciences, Inc. has negative free cash flow, indicating cash burn

Arcus Biosciences, Inc.'s yearly earnings has decreased 24.73% since last year from $-283.00M to $-353.00M, signaling decreasing performance

Arcus Biosciences, Inc.'s yearly revenue has decreased 4.26% since last year from $258.00M to $247.00M, signaling decreasing performance

ROIC -65.76% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Arcus Biosciences, Inc.'s 3-year revenue CAGR of 30.16% is positive, indicating growing revenue over the past 3 years

Arcus Biosciences, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Arcus Biosciences, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Arcus Biosciences, Inc. has insufficient data to evaluate this check.

Arcus Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arcus Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Arcus Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Arcus Biosciences, Inc. is overvalued relative to its fair value price of -69.56 based on Earnings Fair Value model

Arcus Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Arcus Biosciences, Inc. has a price-to-book ratio of 7.81x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Arcus Biosciences, Inc. has a price-to-sales ratio of 30.95x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue